Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Type 2 diabetes mellitus (T2DM) is associated with an elevated risk of cardiovascular (CV) morbidity and mortality. Furthermore, many patients with T2DM have comorbidities that are risk factors for CV disease. While intensive glucose control reduces the risk of diabetic microvascular complications, its relationship to CV outcomes remains unclear. Consequently, the management of CV risk factors in patients with T2DM is complex, and factors other than blood glucose must be considered. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of oral glucose-lowering agents, are associated with reductions in blood pressure and body weight, in addition to decreasing hyperglycemia, and therefore have the potential to reduce CV risk in patients with T2DM. The clinical trial results of SGLT2 inhibitors regarding CV safety and outcomes are discussed, including data from the recently published EMPA-REG OUTCOME study. This trial was the first dedicated CV outcomes study to demonstrate that a glucose-lowering agent lowered CV mortality and all-cause mortality, and reduced hospitalization for heart failure in patients with T2DM at high risk of CV events.

Original languageEnglish (US)
Pages (from-to)398-408
Number of pages11
JournalPostgraduate medicine
Volume128
Issue number4
DOIs
StatePublished - May 18 2016

Fingerprint

Sodium-Glucose Transport Proteins
Type 2 Diabetes Mellitus
Glucose
Mortality
Cardiovascular Agents
Diabetes Complications
Hyperglycemia
Blood Glucose
Comorbidity
Hospitalization
Cardiovascular Diseases
Heart Failure
Body Weight
Outcome Assessment (Health Care)
Clinical Trials
Blood Pressure
Morbidity
Safety

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes. / Steinberg, Helmut.

In: Postgraduate medicine, Vol. 128, No. 4, 18.05.2016, p. 398-408.

Research output: Contribution to journalReview article

@article{e8b3e8d3bfc249e2b4ae7e3c8c8516e9,
title = "Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes",
abstract = "Type 2 diabetes mellitus (T2DM) is associated with an elevated risk of cardiovascular (CV) morbidity and mortality. Furthermore, many patients with T2DM have comorbidities that are risk factors for CV disease. While intensive glucose control reduces the risk of diabetic microvascular complications, its relationship to CV outcomes remains unclear. Consequently, the management of CV risk factors in patients with T2DM is complex, and factors other than blood glucose must be considered. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of oral glucose-lowering agents, are associated with reductions in blood pressure and body weight, in addition to decreasing hyperglycemia, and therefore have the potential to reduce CV risk in patients with T2DM. The clinical trial results of SGLT2 inhibitors regarding CV safety and outcomes are discussed, including data from the recently published EMPA-REG OUTCOME study. This trial was the first dedicated CV outcomes study to demonstrate that a glucose-lowering agent lowered CV mortality and all-cause mortality, and reduced hospitalization for heart failure in patients with T2DM at high risk of CV events.",
author = "Helmut Steinberg",
year = "2016",
month = "5",
day = "18",
doi = "10.1080/00325481.2016.1168687",
language = "English (US)",
volume = "128",
pages = "398--408",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "4",

}

TY - JOUR

T1 - Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes

AU - Steinberg, Helmut

PY - 2016/5/18

Y1 - 2016/5/18

N2 - Type 2 diabetes mellitus (T2DM) is associated with an elevated risk of cardiovascular (CV) morbidity and mortality. Furthermore, many patients with T2DM have comorbidities that are risk factors for CV disease. While intensive glucose control reduces the risk of diabetic microvascular complications, its relationship to CV outcomes remains unclear. Consequently, the management of CV risk factors in patients with T2DM is complex, and factors other than blood glucose must be considered. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of oral glucose-lowering agents, are associated with reductions in blood pressure and body weight, in addition to decreasing hyperglycemia, and therefore have the potential to reduce CV risk in patients with T2DM. The clinical trial results of SGLT2 inhibitors regarding CV safety and outcomes are discussed, including data from the recently published EMPA-REG OUTCOME study. This trial was the first dedicated CV outcomes study to demonstrate that a glucose-lowering agent lowered CV mortality and all-cause mortality, and reduced hospitalization for heart failure in patients with T2DM at high risk of CV events.

AB - Type 2 diabetes mellitus (T2DM) is associated with an elevated risk of cardiovascular (CV) morbidity and mortality. Furthermore, many patients with T2DM have comorbidities that are risk factors for CV disease. While intensive glucose control reduces the risk of diabetic microvascular complications, its relationship to CV outcomes remains unclear. Consequently, the management of CV risk factors in patients with T2DM is complex, and factors other than blood glucose must be considered. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of oral glucose-lowering agents, are associated with reductions in blood pressure and body weight, in addition to decreasing hyperglycemia, and therefore have the potential to reduce CV risk in patients with T2DM. The clinical trial results of SGLT2 inhibitors regarding CV safety and outcomes are discussed, including data from the recently published EMPA-REG OUTCOME study. This trial was the first dedicated CV outcomes study to demonstrate that a glucose-lowering agent lowered CV mortality and all-cause mortality, and reduced hospitalization for heart failure in patients with T2DM at high risk of CV events.

UR - http://www.scopus.com/inward/record.url?scp=84978410005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978410005&partnerID=8YFLogxK

U2 - 10.1080/00325481.2016.1168687

DO - 10.1080/00325481.2016.1168687

M3 - Review article

VL - 128

SP - 398

EP - 408

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 4

ER -